HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

LEADS BIOLABS-B

63.600

-1.950-2.97%

Volume:251.70K

Turnover:16.13M

Market Cap:12.66B

PE:-36.87

High:65.750

Open:65.400

Low:63.250

Close:65.550

52wk High:83.600

52wk Low:57.450

Shares:199.00M

HK Float Shares:153.00M

Volume Ratio:0.40

T/O Rate:0.16%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.725

ROE:--

ROA:--

PB:110.26

PE(LYR):-36.87

PS:- -

Loading ...

Overview Company News Filings

Nanjing Leads Biolabs Narrows H1 Loss; Shares Gain 2%

MT Newswires Live

LEADS BIOLABS-B (09887) Reports Interim Results with Net Loss of Approximately RMB 166 Million, Down 7.8% Year-on-Year

BRIEF-Nanjing Leads Biolabs Posts HY Loss Attributable Of RMB166.4 MLN

Nanjing Leads Biolabs - Hy Loss Attributable RMB166.4 Mln

THOMSON REUTERS

Nanjing Leads Biolabs Doses First Patient in Phase 2 Study of Cancer Drug

MT Newswires Live

Clinical Development Accelerates! LEADS BIOLABS-B (09887) TCE Bispecific Antibody Shows CAR-T Comparable Efficacy in Phase I, First Patient Successfully Dosed in Phase II

Acceleration in Clinical Development! Leads Biolabs' Lbl-034 Dosed First Patient in Phase Ⅱ Trial

THOMSON REUTERS

Nanjing Leads Biolabs' Public Offering Stabilization Period Ends

MT Newswires Live

LEADS BIOLABS-B (09887): Price Stabilization Actions and End of Price Stabilization Period

Hong Kong Stock Alert | LEADS BIOLABS-B (09887) Surges Over 5% Following Completion of Full Patient Enrollment in Key Registration Clinical Study for Opa-Tasumimab

Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma

THOMSON REUTERS

Nanjing Leads Biolabs Raises HK$183 Million from Full Exercise of Overallotment Option in Hong Kong IPO

MT Newswires Live

Nanjing Leads Biolabs Soars 107% in Hong Kong Trading Debut

MT Newswires Live

Stock Track | Nanjing Leads Biolabs Skyrockets 115.71% in Hong Kong Debut, Fueled by Strong Investor Interest and Promising Cancer Therapies

HK Movers | Chinese Biotech Firm Leads Biolabs Soars 122% on Debut

Tiger Newspress

Shares of Nanjing Leads Biolabs Set to Open at HK$72.4 Each in Hong Kong Debut VS Offer Price HK$35 Apiece

THOMSON REUTERS

BRIEF-Nanjing Leads Biolabs Reports Final Offer Price Of Hk$35/H Share

Nanjing Leads Biolabs - Final Offer Price of HK$35.00 per H Share Under Global Offering

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/09887/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":63.6,"timestamp":1757405291391,"preClose":65.55,"halted":0,"volume":251700,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-1.725,"marketStatus":"Closed","change":-1.95,"latestTime":"09-09 16:08:11","open":65.4,"high":65.75,"low":63.25,"amount":16130260,"amplitude":0.038139,"askPrice":63.95,"askSize":200,"bidPrice":63.6,"bidSize":700,"shortable":0,"etf":0,"ttmEps":-1.651777067,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757467800000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":65.55,"openAndCloseTimeList":[[1757381400000,1757390400000],[1757394000000,1757404800000]],"volumeRatio":0.395537,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-1.725,"volumeRatio":0.395537,"shares":199000000,"dividePrice":0,"high":65.75,"amplitude":0.038139,"preClose":65.55,"low":63.25,"week52Low":57.45,"pbRate":"110.26","week52High":83.6,"institutionHeld":0,"latestPrice":63.6,"committee":0.555556,"eps":-1.725,"divideRate":0,"volume":251700,"delay":0,"ttmEps":-1.651777067,"open":65.4,"prevYearClose":35,"prevWeekClose":65.8,"prevMonthClose":66.1,"prevQuarterClose":35,"fiveDayClose":63.5,"twentyDayClose":68.35,"sixtyDayClose":35},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2025-09-08","current":-41.529824,"percent":0.645161,"low":-47.422411,"twenty":-44.071038,"median":-41.935668,"eighty":-40.73232,"high":-37.26013,"avg":-42.369566,"sd":2.306377,"marketCap":13037357490},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-08","current":-41.529824,"twenty":-44.071038,"median":-41.935668,"eighty":-40.73232,"marketCap":13037357490}],"updateTime":1757387989585},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2564818851","title":"Nanjing Leads Biolabs Narrows H1 Loss; Shares Gain 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2564818851","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564818851?lang=en_us&edition=fundamental","pubTime":"2025-09-01 16:56","pubTimestamp":1756717019,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs  posted a loss attributable to owners of 166.4 million yuan for the first half of 2025, compared with a 180.4 million yuan loss a year earlier, according to an Aug. 29 Hong Kong bourse filing.Shares of the clinical-stage biotech were up nearly 2% in Monday afternoon trade.Loss per share was 1.06 yuan, compared with 1.22 yuan in the same period last year.It reported no nil revenue for the reporting period.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"1107800699","title":"LEADS BIOLABS-B (09887) Reports Interim Results with Net Loss of Approximately RMB 166 Million, Down 7.8% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1107800699","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107800699?lang=en_us&edition=fundamental","pubTime":"2025-08-29 22:06","pubTimestamp":1756476375,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced its interim results for 2025, with research and development costs of approximately RMB 132 million, representing a 56.9% year-on-year increase. The company recorded...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2563213960","title":"BRIEF-Nanjing Leads Biolabs Posts HY Loss Attributable Of RMB166.4 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2563213960","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563213960?lang=en_us&edition=fundamental","pubTime":"2025-08-29 21:52","pubTimestamp":1756475532,"startTime":"0","endTime":"0","summary":"BRIEF-Nanjing Leads Biolabs Posts HY Loss Attributable Of RMB166.4 MLNAug 29 (Reuters) - Nanjing Leads Biolabs Co Ltd 9887.HK:HY LOSS ATTRIBUTABLE RMB166.4 MILLIONFurther company coverage: 9887.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nFWN3UL112:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2563260900","title":"Nanjing Leads Biolabs - Hy Loss Attributable RMB166.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2563260900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563260900?lang=en_us&edition=fundamental","pubTime":"2025-08-29 21:21","pubTimestamp":1756473700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nFWN3UL112:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2562731249","title":"Nanjing Leads Biolabs Doses First Patient in Phase 2 Study of Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2562731249","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562731249?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:08","pubTimestamp":1756123683,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs (HKG:9887) dosed the first patient in a phase 2 trial of LBL-034 following strong phase I data, a Monday filing with the Hong Kong bourse said.The study aims to evaluate the effi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"1194708533","title":"Clinical Development Accelerates! LEADS BIOLABS-B (09887) TCE Bispecific Antibody Shows CAR-T Comparable Efficacy in Phase I, First Patient Successfully Dosed in Phase II","url":"https://stock-news.laohu8.com/highlight/detail?id=1194708533","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194708533?lang=en_us&edition=fundamental","pubTime":"2025-08-25 19:14","pubTimestamp":1756120487,"startTime":"0","endTime":"0","summary":"On August 25, LEADS BIOLABS-B (09887) announced that the company's independently developed GPRC5D/CD3 bispecific antibody has successfully completed enrollment of the first patient in its Phase II...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","CAR","BK1161","BK4022","BK4230"],"gpt_icon":0},{"id":"2562488202","title":"Acceleration in Clinical Development! Leads Biolabs' Lbl-034 Dosed First Patient in Phase Ⅱ Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2562488202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562488202?lang=en_us&edition=fundamental","pubTime":"2025-08-25 18:19","pubTimestamp":1756117179,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nTUABQ2XM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2561204384","title":"Nanjing Leads Biolabs' Public Offering Stabilization Period Ends","url":"https://stock-news.laohu8.com/highlight/detail?id=2561204384","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561204384?lang=en_us&edition=fundamental","pubTime":"2025-08-22 17:45","pubTimestamp":1755855953,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs  said the stabilization period of its Hong Kong listing ended on Thursday, Aug. 21, according to a same-day Hong Kong bourse filing.Shares of the company closed 4% lower on Friday.The IPO's stabilizing manager overallocated 12,821,700 H shares in the international portion of the offering, while underwriters fully exercised their overallotment option to purchase 5,529,300 shares.No H shares were sold or purchased on the market during the stabilization period, the company said.The biotech company said its public float continues to comply with Hong Kong's listing requirements.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"1147682152","title":"LEADS BIOLABS-B (09887): Price Stabilization Actions and End of Price Stabilization Period","url":"https://stock-news.laohu8.com/highlight/detail?id=1147682152","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147682152?lang=en_us&edition=fundamental","pubTime":"2025-08-21 18:42","pubTimestamp":1755772951,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the price stabilization period in relation to its global offering concluded on August 21, 2025 (Thursday), being the 30th day after the deadline for submitting...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":1},{"id":"1141203517","title":"Hong Kong Stock Alert | LEADS BIOLABS-B (09887) Surges Over 5% Following Completion of Full Patient Enrollment in Key Registration Clinical Study for Opa-Tasumimab","url":"https://stock-news.laohu8.com/highlight/detail?id=1141203517","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141203517?lang=en_us&edition=fundamental","pubTime":"2025-08-18 14:38","pubTimestamp":1755499104,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) surged over 5%, rising 4.54% to HK$72.5 with trading volume of HK$86.43 million at the time of reporting. On the news front, the company announced on August 14 that the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":1},{"id":"2559953217","title":"Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2559953217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559953217?lang=en_us&edition=fundamental","pubTime":"2025-08-14 17:24","pubTimestamp":1755163448,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nTUA7S0MBZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2557581222","title":"Nanjing Leads Biolabs Raises HK$183 Million from Full Exercise of Overallotment Option in Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2557581222","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557581222?lang=en_us&edition=fundamental","pubTime":"2025-08-07 09:42","pubTimestamp":1754530964,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs  said the underwriters of its Hong Kong listing fully-exercised their overallotment option, according to a Hong Kong bourse filing Thursday.Shares of the biotech company jumped over 2% in recent trade.The company will issue a further 5,529,300 shares at HK$35 apiece to raise HK$183.8 million.Funds will be funneled toward the company's ongoing and planned clinical development and regulatory affairs, advancement of its preclinical assets, commercialization of its drug candidates, and for working capital and general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","09887"],"gpt_icon":1},{"id":"2554325397","title":"Nanjing Leads Biolabs Soars 107% in Hong Kong Trading Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2554325397","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554325397?lang=en_us&edition=fundamental","pubTime":"2025-07-25 09:57","pubTimestamp":1753408670,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs (HKG:9887) made a stellar trading debut in Hong Kong Friday morning as its shares opened 107% above the IPO price.The clinical-stage biotech company opened at HK$72.40 per share, compared with the IPO price of HK$35.00.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"6781511e19081bc3c1e0645670779555","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09887"],"gpt_icon":0},{"id":"1187258210","title":"Stock Track | Nanjing Leads Biolabs Skyrockets 115.71% in Hong Kong Debut, Fueled by Strong Investor Interest and Promising Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=1187258210","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187258210?lang=en_us&edition=fundamental","pubTime":"2025-07-25 09:33","pubTimestamp":1753407180,"startTime":"0","endTime":"0","summary":"Shares of Nanjing Leads Biolabs (HKG:9887) soared 115.71% in their trading debut on the Hong Kong Stock Exchange, reflecting strong investor enthusiasm for the clinical-stage biotech company's...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"6781511e19081bc3c1e0645670779555","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09887"],"gpt_icon":1},{"id":"1198634791","title":"HK Movers | Chinese Biotech Firm Leads Biolabs Soars 122% on Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1198634791","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198634791?lang=en_us&edition=fundamental","pubTime":"2025-07-25 09:30","pubTimestamp":1753407041,"startTime":"0","endTime":"0","summary":"Chinese biotech firm $Leads Biolabs(09887)$ shares soared 81% in Hong Kong grey market.The biotech sector has faced heightened volatility in 2025, with investors scrutinizing clinical trial outcomes...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"6781511e19081bc3c1e0645670779555","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"2554734612","title":"Shares of Nanjing Leads Biolabs  Set to Open at HK$72.4 Each in Hong Kong Debut VS Offer Price HK$35 Apiece","url":"https://stock-news.laohu8.com/highlight/detail?id=2554734612","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554734612?lang=en_us&edition=fundamental","pubTime":"2025-07-25 09:20","pubTimestamp":1753406437,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250725:nL4N3TM031:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887"],"gpt_icon":0},{"id":"2553078993","title":"BRIEF-Nanjing Leads Biolabs Reports Final Offer Price Of Hk$35/H Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2553078993","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553078993?lang=en_us&edition=fundamental","pubTime":"2025-07-24 22:57","pubTimestamp":1753369052,"startTime":"0","endTime":"0","summary":"BRIEF-Nanjing Leads Biolabs Reports Final Offer Price Of Hk$35/H ShareJuly 24 (Reuters) - Nanjing Leads Biolabs 9887.HK:FINAL OFFER PRICE OF HK$35.00 PER H SHARE UNDER GLOBAL OFFERINGFurther company coverage: 9887.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nFWN3TL1IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"2553514789","title":"Nanjing Leads Biolabs -  Final Offer Price of HK$35.00 per H Share Under Global Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2553514789","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553514789?lang=en_us&edition=fundamental","pubTime":"2025-07-24 22:38","pubTimestamp":1753367938,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nFWN3TL1IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}